Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Data on Once-Daily Extended Release Pramipexole Presented at 13th International Congress of Parkinson’s Disease and Movement Disorders (MDS)

PARIS--(BUSINESS WIRE)--New data presented today at the Movement Disorder Society’s 13th International Congress of Parkinson’s Disease and Movement Disorders (MDS) suggest that pramipexole once-daily, extended release (ER) formulation is comparable to pramipexole immediate release (IR) formulation in patients with advanced Parkinson’s disease (PD). These data support the results from a previous trial that assessed the efficacy, safety and tolerability of the once-daily ER formulation in the treatment of early PD after 18 weeks, and non-inferiority between pramipexole ER and pramipexole IR after 33 weeks, as presented for the first time today at the MDS.

Back to news